Radiation-related Changes in Serum Proteome Profiles Detectedby Mass Spectrometry in Blood of Patients Treatedwith Radiotherapy Due to Larynx Cancer

Journal of Radiation Research

Volumn 52, Issue 5, 2011, Pages 575-581

  WidŁak, Piotr ^a   Pietrowska, Monika ^a   Wojtkiewicz, Katarzyna ^b   Rutkowski, Tomasz ^a   Wygoda, Andrzej ^a   Marczak, Łukasz ^c   Marczyk, MichaŁ ^b   Polańska, Joanna ^b   Walaszczyk, Anna ^a   Domińczyk, Iwona ^a   SkŁadowski, Krzysztof ^a   Stobiecki, Maciej ^c   Polański, Andrzej ^b,d  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b SILESIAN UNIVERSITY OF TECHNOLOGY   (Poland)

^c INSTITUTE OF BIOORGANIC CHEMISTRY   (Poland)

^d POLISH JAPANESE INSTITUTE OF INFORMATION TECHNOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD; DISEASES; IONIZING RADIATION; MASS SPECTROMETRY; PATIENT MONITORING; PEPTIDES; RADIATION SHIELDING;

BLOOD SAMPLES; HUMAN SERUM PROTEOME; LARYNX CANCER; LOW MOLECULAR WEIGHT; MOLECULAR WEIGHT FRACTION; PEPTIDES IONS; RADICAL RADIOTHERAPY; SERUM SAMPLES; TOF MASS SPECTROMETRY; TOTAL DOSE;

RADIOTHERAPY;

EID: 80053342878     PISSN: 04493060     EISSN: 13499157     Source Type: Journal    
DOI: 10.1269/jrr.11019     Document Type: Article

References (32)

1. Bentzen SM (2008) From cellular to high-throughput predictive assays in radiation oncology: challenges and opportunities. Sem Radiat Oncol 18: 75-88.
2. Nuyten DS and van de Vijver MJ (2008) Using microarray analysis as a prognostic and predictive tool in oncology: focus on breast cancer and normal tissue toxicity. Sem Radiat Oncol 18: 105-114.
3. Wouters BG (2008) Proteomics: methodologies and applications in oncology. Sem Radiat Oncol 18: 115-125.
4. Alsner J, Andreassen CN and Overgaard J (2008) Genetic markers for prediction of normal tissue toxicity after radiotherapy. Sem Radiat Oncol 18: 126-135.
5. Horneck G (1998) Biological monitoring of radiation exposure. Adv Space Res 22: 1631-1641.
6. Amundson SA, Bittner M and Fornace AJ (2003) Functional genomics as a window on radiation stress signaling. Oncogene 22: 5828-5833.
7. Wulfkuhle JD, Liotta LA and Petricoin EF (2003) Proteomic applications for the early detection of cancer. Nature Rev Cancer 3: 267-275.
8. Liotta LA, Ferrari M and Petricoin EF (2003) Clinical proteomics: written in blood. Nature 425: 905.
9. Liotta LA and Petricoin EF (2006) Serum peptidome for cancer detection: spinning biological trash into diagnostic gold. J Clin Invest 116: 26-30.
10. Li L, et al (2004) Data mining techniques for cancer detection using serum proteomic profiling. Artif Intell Med 32: 71-83.
11. Dworzanski JP and Snyder AP (2005) Classification and identification of bacteria using mass spectrometry-based proteomics. Expert Rev Proteomics 2: 863-878.
12. Somorjai RL (2008) Pattern recognition approaches for classifying proteomic mass spectra of biofluids. Methods Mol Biol 428: 383-396.
13. Conrads TP, et al (2004) Proteomic patterns as a diagnostic tool for early-stage cancer: a review of its progress to a clinically relevant tool. Mol Diagn 8: 77-85.
14. Posadas EM, et al (2005) Proteomic analysis for the early detection and rational treatment of cancer-realistic hope? Ann Oncol 16: 16-22.
15. Azad NS, et al (2006) Proteomics in clinical trials and practice. Mol Cell Proteomics 5: 1819-1829.
16. Solassol J, et al (2006) Clinical proteomics and mass spectrometry profiling for cancer detection. Expert Rev Proteomics 3: 311-320.
17. Cho WCS (2007) Contribution of oncoproteomics to cancer biomarker discovery: Mol Cancer 6: e25.
18. Palmblad M, Tiss A and Cramer R (2009) Mass spectrometry in clinical proteomics - from the present to the future. Proteomics Clin Appl 3: 6-17.
19. Pusztai L, et al (2004) Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma. Cancer 100: 1814-1822.
20. Heike Y, et al (2005) Identification of serum proteins related to adverse effects induced by docetaxel infusion from protein expression profiles of serum using SELDI ProteinChip system. Anticancer Res 25: 1197-1203.
21. Goncalves A, et al (2006) Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy. Oncogene 25: 981-989.
22. Menard C, et al (2006) Discovering clinical biomarkers of ionizing radiation exposure with serum proteomic analysis. Cancer Res 66: 1844-1850.
23. Gourin CG, et al (2007) Serum protein profile analysis following definitive treatment in patients with head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 133: 1125-1130.
24. Freed GL, et al (2008) Differential capture of serum proteins for expression profiling and biomarker discovery in pre- and post-treatment head and neck cancer samples. Laryngoscope 118: 61-68.
25. Pietrowska M, et al (2010) Mass spectrometry-based analysis of therapy-related changes in serum proteome patterns of patients with early stage breast cancer. J Translat Med 8: e66.
26. Karpievitch YV, et al (2007) PrepMS: TOF MS Data Graphical Preprocessing Tool. Bioinformatics 23: 264-265.
27. Hilario M, et al (2006) Processing and classification of protein mass spectra. Mass Spectrom Rev 25: 409-449.
28. Wong JWH, Cagney G and Cartwright HM (2005) SpecAlign - processing and alignment of mass spectra datasets. Bioinformatics 21: 2088-2090.
29. Lustgarten JL, et al (2008) EPO-KB: a searchable knowledge base of biomarker to protein links. Bioinformatics 24: 1418-1419.
30. Wygoda A, et al (2009) Pattern analysis of acute mucosal reactions in patients with head and neck cancer treated with conventional and accelerated irradiation. Int J Radiation Oncol Biol Phys 73: 384-390.
31. Villanueva J, et al (2006) Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 116: 271-284.
32. Callesen AK, et al (2008) Reproducibility of mass spectrometry based protein profiles for diagnosis of breast cancer across clinical studies: a systematic review. J Proteome Res 7: 1395-1402.